Business news for the stock market
Leverkusen, Germany (pta016/16.11.2022/12:35) - Biofrontera AG (FSE: B8F), an international biopharmaceutical company, appoints Dr. Axel Drews as Vice President Global Sales & Marketing.
In his position, Dr. Drews is responsible for the development of global sales strategies and the access to new country markets as well as the successful management and integration of the existing sales organizations into a global strategic approach.
The evaluation of market potentials and the analysis of existing sales structures will be part of his main tasks besides the development of efficient go-to-market strategies.
Dr. Drews has 24 years of marketing and sales experience in the healthcare sector, especially in the European business, most recently 3 years as Vice President Commercial at Paion AG.
Previously, he held various positions in marketing and sales at Grünenthal GmbH from 2009 to 2019, where he also held the position of Vice President Marketing and Sales in the German division.
"With Dr. Drews, we have been able to gain an extremely experienced and strategically oriented global head of sales, who will now support Biofrontera in strengthening its European business and who will develop long-term strategies to establish Biofrontera as a global player in dermatology. We are very pleased to have Dr. Drews joined our team and with his appointment we have established a key position within the company which is essential for Biofrontera's successful future ", comments Pilar de la Huerta, CFO of Biofrontera AG.
Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics. The Leverkusen-based company develops and markets innovative products for the treatment, protection and care of the skin. Its key products include Ameluz®, a prescription drug for the treatment of non-melanoma skin cancer and its precursors. Ameluz® has been marketed in the EU since 2012 and in the USA since May 2016. In Europe, the company also markets the Belixos® dermocosmetic series, a specialty care product for damaged skin. Biofrontera is one of a few German pharmaceutical company to receive a centralized European and a US approval for a drug developed in-house. The Biofrontera Group was founded in 1997 and is listed on the Frankfurt Stock Exchange (Prime Standard). www.biofrontera.com
Forward-Looking Statements: Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "will," "anticipate," "believe," "forecast," "estimate" and "intend," among others. Such forward-looking statements are based on the currently held beliefs and assumptions of the management of Biofrontera AG, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, including, but not limited to, the risk that the termination of the ADS Level 1 Program or the deregistration with the SEC may not occur or may be delayed, which may cause the actual results, financial condition, performance, or achievements of the Company, or industry results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. Given these risks, uncertainties and other factors, prospective investors are cautioned not to place undue reliance on these forward-looking statements. The Company does not undertake an obligation to update or revise any forward-looking statement.
emitter: Biofrontera AG
address: Hemmelrather Weg 201, 51377 Leverkusen
contact person: Investor Relations
phone: +49 (0) 214 87 63 20
ISIN(s): DE0006046113 (share)
stock exchanges: regulated market in Frankfurt, Dusseldorf; free market in Stuttgart, free market in Munich; open market in Berlin, Tradegate